ORIGINAL ARTICLE

Serum sex hormone-binding globulin levels are reduced and inversely associated with intrahepatic lipid content and saturated fatty acid fraction in adult patients with glycogen storage disease type 1a

P. I. H. G. Simons[1,2,3] · O. Valkenburg[4] · I. Telgenkamp[1,2] · K. M. van der Waaij[1,2] · D. M. de Groot[1] · P. Veeraiah[5,6] ·
J. A. P. Bons[7] · T. G. J. Derks[8] · C. G. Schalkwijk[2,3,9] · V. B. Schrauwen-Hinderling[5,6] · C. D. A. Stehouwer[2,3,9] ·
M. C. G. J. Brouwers[1,3]

Abstract

Purpose De novo lipogenesis has been inversely associated with serum sex hormone-binding globulin (SHBG) levels. However, the directionality of this association has remained uncertain. We, therefore, studied individuals with glycogen storage disease type 1a (GSD1a), who are characterized by a genetic defect in glucose-6-phosphatase resulting in increased rates of de novo lipogenesis, to assess the downstream effect on serum SHBG levels.

Methods A case–control study comparing serum SHBG levels in patients with GSD1a ($n = 10$) and controls matched for age, sex, and BMI ($n = 10$). Intrahepatic lipid content and saturated fatty acid fraction were quantified by proton magnetic resonance spectroscopy.

Results Serum SHBG levels were statistically significantly lower in patients with GSD1a compared to the controls ($p = 0.041$), while intrahepatic lipid content and intrahepatic saturated fatty acid fraction—a marker of de novo lipogenesis—were significantly higher in patients with GSD1a ($p = 0.001$ and $p = 0.019$, respectively). In addition, there was a statistically significant, inverse association of intrahepatic lipid content and saturated fatty acid fraction with serum SHBG levels in patients and controls combined (β: − 0.28, 95% CI: − 0.47;− 0.09 and β: − 0.02, 95% CI: − 0.04;− 0.01, respectively).

Conclusion Patients with GSD1a, who are characterized by genetically determined higher rates of de novo lipogenesis, have lower serum SHBG levels than controls.

Keywords Glycogen storage disease type 1a · De novo lipogenesis · Intrahepatic lipid content · Sex hormone-binding globulin

✉ M. C. G. J. Brouwers
mcgj.brouwers@mumc.nl

1 Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands

2 Laboratory for Metabolism and Vascular Medicine, Maastricht University, Maastricht, The Netherlands

3 CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands

4 Department of Reproductive Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands

5 Department of Nutrition and Movement Sciences, Maastricht University, Maastricht, The Netherlands

6 Department of Radiology and Nuclear Medicine, Maastricht University, Maastricht, The Netherlands

7 Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands

8 Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

9 Division of General Internal Medicine, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands

Introduction

It has long been thought that sex hormone-binding globulin (SHBG) acts only as a simple carrier protein that regulates the bioavailable fraction of testosterone and other sex hormones [1]. In the past decades, however, serum SHBG has also been inversely associated with several metabolic disorders, including obesity, non-alcoholic fatty liver disease, and type 2 diabetes [2–4]. Even more recently, SHBG has been identified as a hepatokine that protects from type 2 diabetes [5, 6]. These observations stress the need for a better understanding of the regulation of serum SHBG levels in humans.

In vitro and animal studies have shown that carbohydrate-induced de novo lipogenesis is one of the mechanisms involved in the downregulation of SHBG levels [7]. We have recently extrapolated these findings to humans, by showing that de novo lipogenesis, measured with stable isotopes, is inversely associated with serum SHBG levels [8]. However, given the observational nature of that study, we were unable to assess whether the effect of de novo lipogenesis on serum SHBG is causal. This is of importance, since previous in vitro and animal studies have shown that the association between de novo lipogenesis and SHBG appears to be bidirectional, i.e. serum SHBG may also directly reduce the rates of de novo lipogenesis [9, 10].

Monogenetic disorders that affect de novo lipogenesis can be used to unravel whether there is a causal effect of de novo lipogenesis on serum SHBG, in humans. Glycogen storage disease type 1a (GSD1a) is an inborn error of metabolism, caused by a mutation in the *G6PC* gene encoding glucose-6-phosphatase [11]. As a consequence, there is an intrahepatic surplus of glucose-6-phosphate that can serve as a substrate for glycolysis and de novo lipogenesis. Previous studies have shown that patients with GSD1a are indeed characterized by higher rates of de novo lipogenesis and intrahepatic saturated fatty acid (SFA) fraction, the product of de novo lipogenesis [12, 13].

The aim of this study was, therefore, to examine serum SHBG levels in patients with GSD1a and controls matched for age, sex, and BMI, and to study the relationship of intrahepatic lipid (IHL) and SFA content with serum SHBG.

Methods

Study design

For this case–control study, we recruited homozygous carriers of a mutation in the gene encoding glucose-6-phosphatase (*G6PC*), causing GSD1a, from outpatient metabolic clinics in the Netherlands and Belgium. Cases were matched to controls based on factors that are known to affect serum SHBG levels, i.e. age, sex, and BMI [14, 15]. To accomplish an adequate matching, we retrieved data for controls from (1) the effects of fructose restriction on liver steatosis [FRUITLESS] study [16], (2) the aldolase B deficiency study [17], and (3) prospective recruitment through local advertisement. All study protocols were similar, with the exception of differences in in- and exclusion criteria. The rationale and design of the FRUITLESS and aldolase B deficiency studies have been published previously. In short, the FRUITLESS study was originally conducted to assess the effects of fructose restriction on IHL content [16]. Participants were included if they had a fatty liver index ≥ 60, and excluded in case of a history of liver disease, excessive alcohol consumption, change in weight or physical activity 3 months prior to participation, use of glucose-lowering drugs, recent illness, pregnancy and/or lactation [16]. For the current study, only data from baseline measurements were used. The aldolase B deficiency case–control study was originally conducted to compare IHL content in patients with hereditary fructose intolerance and controls. Only data from controls was used in this study [17]. All studies were performed according to the Declaration of Helsinki and approved by the Medical Ethical Committee of Maastricht University Medical Centre [18]. All participants gave written informed consent prior to participation.

All participants had to be at least 18 years of age and were excluded from participation if they had any contraindications for magnetic resonance imaging (MRI) or were unable to give informed consent. Furthermore, as oestrogen-containing medication, which substantially affects serum SHBG levels, are relatively contra-indicated in GSD1a [19–21], controls were excluded if they used oestrogen-containing medication. All controls were asked to visit the metabolic ward after an overnight fast. Since patients with GSD1a develop hypoglycaemia and lactic acidosis upon prolonged fasting, they are treated with either (modified) uncooked cornstarch at night or continuous nocturnal feeding with dextrose [11]. They were, therefore, asked to visit the metabolic ward before having breakfast.

Measurements

For all participants, anthropometrics and quantification of IHL content by proton magnetic resonance spectroscopy (^{1}H-MRS) using a 3T clinical MR scanner (Achieva 3T-X, Philips Healthcare, Best, the Netherlands), were performed as described previously [17]. In a subset of GSD1a patients and controls, the hepatic SFA fraction (expressed as the ratio SFA:IHL * 100%) was quantified with a newly developed

Table 1 Characteristics of controls and patients with glycogen storage disease type 1a (GSD1a)

	Control (*n* = 10)	GSD1a (*n* = 10)
Sex (male/female), *n/n*	3/7	3/7
Age, years	32.5 (20.0–56.3)	29.5 (21.5–47.0)
BMI, kg/m^2	26.0 (22.2–31.5)	25.5 (24.5–28.5)
Waist circumference, cm	93.6 (80.5–110.0)	93.5 (82.8–100.4)
Systolic blood pressure, mmHg	129 (112–138)	125 (105–134)
Diastolic blood pressure, mmHg	79 (65–84)	76 (64–81)
Glucose, mmol/l[#]	4.5 (4.2–5.0)	4.4 (3.4–4.8)
Insulin, pmol/l	28.7 (23.0–67.2)	16.5 (10.0–26.6)*
Uric acid, mmol/l	0.34 (0.30–0.35)	0.37 (0.26–0.47)
Total cholesterol, mmol/l	5.1 (4.1–5.4)	5.5 (4.8–6.9)
HDL-cholesterol, mmol/l	1.2 (1.1–1.5)	0.9 (0.7–1.0)*
Triglycerides, mmol/l	1.3 (1.0–1.6)	4.9 (3.7–6.3)*
Alcohol consumption (units/week)	0.2 (0.0–5.0)	0.0 (0.0–0.3)

Unless otherwise noted, data are expressed as median (interquartile range)

BMI body mass index, *GSD1a* glycogen storage disease type 1a, *HDL* high density lipoprotein, *LDL* low density lipoprotein

*$p < 0.05$ compared to controls, analysed with Mann–Whitney *U* test

[#]Serum glucose was measured with enzymatic spectrophotometric assay in GSD1a and with enzymatic spectrophotometric assay YSI2300

STAT Plus Glucose Lactate Analyzer in controls, see "Methods" section

^{1}H-MRS method. We previously showed that this fraction correlates well with de novo lipogenesis assessed by stable isotopes [13]. Serum uric acid, total cholesterol, HDL cholesterol, and triglycerides were measured with an enzymatic colorimetric assay (Cobas 8000 instrument, Roche Diagnostics, Mannheim, Germany). Serum glucose was measured with an enzymatic spectrophotometric assay in patients with GSD1a and a subset of the controls (Cobas 8000 instrument, Roche Diagnostics, Mannheim, Germany). In the controls originating from the aldolase B deficiency and FRUITLESS studies, serum glucose was measured with YSI2300 STAT Plus Glucose Lactate Analyzer (YSI, Yellow Springs, OH, USA) [16, 17]. Serum insulin and SHBG were measured with a chemiluminescent immunometric assay in all participants (Immulite XPi instrument, Siemens Healthcare Diagnostics, New Orleans, LA, USA). Serum SHBG measurements demonstrated an analytical variability of 5–7%, with an intra-individual biological variability of 9% [22]. In one patient with GSD1a, blood was drawn directly after the consumption of food, and hence this individual was not included in the analyses of fasting-sensitive measures (i.e., serum lipids, glucose and insulin).

Statistical analyses

Continuous data are presented as median (interquartile range) and categorical data are presented as frequencies. Continuous variables were compared between GSD1a patients and controls by means of Mann–Whitney *U* test. Univariate regression analyses were performed to study the association of BMI, serum insulin, IHL content and SFA fraction with serum SHBG levels. The univariate regression analyses were additionally stratified by condition (i.e., GSD1a or controls). All results were considered statistically significant at $p < 0.05$. All statistical analyses were performed using IBM Statistical Package of Social Science (SPSS) version 25.0 for Windows (IBM Corp., Armonk, N.Y., USA).

Results

Population characteristics

The general characteristics of the patients with GSD1a (*n* = 10) and matched controls (*n* = 10; *n* = 5 from FRUITLESS, *n* = 3 from the aldolase B deficiency study, and *n* = 2 prospectively recruited) are shown in Table 1. The majority of the study population was female (70%), young (median age: 31.0, IQR: 20.5–47.0 years) and overweight (median BMI: 25.5, IQR: 23.6–29.7 kg/m^2). Age, sex distribution and BMI were, by design, comparable between GSD1a patients and controls (Table 1). Serum triglycerides were statistically significantly higher in individuals with GSD1a, while HDL-cholesterol was significantly lower in patients with GSD1a compared to controls (Table 1).

Patients with GSD1a had statistically significantly lower levels of serum insulin compared to controls ($p = 0.009$) (Fig. 1, panel A), while the IHL content and SFA fraction in patients with GSD1a were statistically significantly higher compared to controls ($p = 0.001$ and $p = 0.019$, respectively) (Fig. 1, panel B and C, respectively). Serum SHBG levels were statistically significantly lower in GSD1a patients compared to the controls (13.0 nmol/l [IQR: 10.8–25.3] versus 29.5 nmol/l [IQR: 18.5–34.8], respectively; $p = 0.041$; Fig. 1, panel D). As one male patient used pregnyl (i.e., human chorionic gonadotropin), which may potentially influence serum SHBG levels [23], we repeated the analyses after exclusion of this patient and the matched control, which did not affect the results ($p = 0.050$).

Strikingly, two female patients with GSD1a were found to have high serum SHBG levels relative to the other (female) GSD1a patients, and were notable outliers (Fig. 1, panel D, open circles). Of interest, these two patients also seemed metabolically healthier, as indicated by relatively low serum

Fig. 1 Serum insulin (**A**), intrahepatic lipid (IHL) content (**B**), saturated fatty acid (SFA) fraction (**C**) and serum sex hormone-binding globulin (SHBG) (**D**) in patients with glycogen storage disease type 1a (GSD1a) and controls matched for age, sex, and BMI. Data expressed as individual values with median. Open circles represent GSD1a patients with exceptionally high serum SHBG levels. Differences between the groups were analysed with a Mann–Whitney U test. Of note, fasting serum insulin was unavailable in one GSD1a patient, and SFA fraction was only measured in a subset of cases ($n=8$) and controls ($n=5$) (see "Methods" section)

insulin levels, IHL content, and SFA fraction compared to the values seen for the other patients with GSD1a (Fig. 1, panel A, B, and C; open circles), whereas serum triglycerides and urate did not appear to differ (data not shown).

Determinants of serum SHBG

In the overall population there was no statistically significant association between BMI or insulin with serum SHBG levels (β: 0.00, 95% CI: −0.03;0.04 and β: 0.00, 95% CI: −0.01;0.01, respectively), or after stratification by condition in the GSD1a group (β: 0.02, 95% CI: −0.06;0.10 and β: −0.02, 95% CI: −0.04;0.01, respectively), or in controls (β: -0.01, 95% CI: −0.04;0.03 and β: 0.00, 95% CI: −0.01;0.01, respectively) (Fig. 2, panel A and B, respectively). In contrast, there was a statistically significant, inverse association between IHL content and serum SHBG levels in the overall population (β: −0.28, 95% CI: −0.47;−0.09, Fig. 2,

Fig. 2 Association of body mass index (BMI) (**A**) serum insulin (**B**) intrahepatic lipid (IHL) content (**C**), and saturated fatty acid (SFA) fraction (**D**) with serum sex hormone-binding globulin (SHBG) levels stratified by glycogen storage disease type 1a (closed circles) and controls matched for age, sex, and BMI (open circles). Regression coefficients (β) and 95% confidence intervals (CI) are reported for the associations in the two groups combined. Of note, fasting serum insulin was unavailable in one GSD1a patient, and SFA was only measured in a subset of patients ($n=8$) and controls ($n=5$) (see "Methods" section)

panel C). After stratification for condition, the association remained statistically significant only in patients with GSD1a (GSD1a: β: − 0.47, 95% CI: − 0.83;− 0.10, controls: β: − 0.07, 95% CI: − 0.57;0.44). The SFA fraction was also statistically significantly inversely associated with lower serum SHBG levels in the overall population (β: − 0.02, 95% CI: − 0.04;− 0.01; Fig. 2, panel D). Stratified analyses showed a significant, inverse association in GSD1a but not in the controls (β: − 0.06, 95% CI: − 0.08;− 0.03 and β: − 0.01, 95% CI: − 0.05;0.03, respectively).

Discussion

This study shows that serum SHBG levels are statistically significantly lower in adult patients with GSD1a when compared to controls matched for age, sex, and BMI. In addition, serum SHBG levels varied noticeably within the GSD1a group and appeared to correspond with the variation of other metabolic variables, i.e., IHL content, SFA fraction and serum insulin levels. Indeed, there was a statistically significant, inverse association of IHL content and SFA fraction with serum SHBG levels in patients with GSD1a and controls combined.

The current findings support and elaborate on previous experimental and observational studies. In vitro studies have shown that monosaccharide-induced de novo lipogenesis downregulates hepatocyte nuclear factor 4 alpha, thereby decreasing SHBG synthesis in HepG2 cells [7]. In addition, incubation of HepG2 cells with palmitate, the product of de novo lipogenesis, was also found to decrease SHBG levels [7]. Although we have previously extrapolated these in vitro findings to humans by showing that de novo lipogenesis, assessed with stable isotopes, was inversely associated

with serum SHBG levels, we could not assess the direction of the association [8]. This is of relevance, since in vitro experiments have also shown that SHBG can affect de novo lipogenesis [9]. By studying patients with GSD1a, who are characterized by a primary genetic defect resulting in high intrahepatic glucose-6-phosphate levels and, consequently, higher rates of de novo lipogenesis [11, 12, 24], our current observations support the concept that de novo lipogenesis results in lower serum SHBG levels in humans. This conclusion, however, deserves some caution given the small, predominantly female population that was studied, which limits the generalisability of the our findings. Furthermore, our observations do not exclude the reverse, i.e., SHBG affects de novo lipogenesis in humans.

The current findings are in line with large population studies that assessed the effect of a common variant in the glucokinase regulatory protein gene (*GCKR*), which also results in higher intrahepatic glucose-6-phosphate levels and rates of de novo lipogenesis, albeit by a different mechanism. Similar to patients with GSD1a, individuals carrying the *GCKR* minor allele are characterized by lower fasting glucose and insulin levels, higher serum triglycerides, higher rates of de novo lipogenesis and a higher IHL content [25–29]. Previous genome-wide association studies have reported that the *GCKR* minor allele is also associated with lower serum SHBG levels [5, 30].

Besides a better knowledge on the causal role of de novo lipogenesis on serum SHBG in humans, the results of this study may also have several clinical implications for patients with GSD1a. First, as recent Mendelian randomization studies have shown that SHBG is causal in the pathogenesis of polycystic ovary syndrome (PCOS), the low serum SHBG levels may contribute to the higher prevalence of PCOS that has been observed in GSD1a [31, 32]. Second, we noted that two female patients with GSD1a with relatively high levels of serum SHBG were also characterized by a better metabolic control with respect to IHL content and SFA fraction. Serum SHBG could, therefore, serve as a biomarker of metabolic control in patients with GSD1a. In comparison to current measures of metabolic control (e.g., serum triglycerides), serum SHBG has several advantages. The half-life of serum SHBG is relatively long (7 days) and can, therefore, reflect metabolic control over the past days [33]. In addition, serum SHBG levels are not directly affected by the nutritional state, i.e., fasted or fed, in contrast to serum triglycerides. Further studies are needed to assess whether intra-individual variations in serum SHBG adequately reflect changes in metabolic control in GSD1a patients.

This study has several strengths and limitations. The use of GSD1a as a model for higher rates of de novo lipogenesis is a unique approach to study the direct effects of de novo lipogenesis on serum SHBG levels in an observational setting. However, the rare nature of this disease

(prevalence ~ 1 in 100,000 births [34]) results in small numbers and, consequently, low statistical power, in particular for the stratified univariate analyses. In addition, as a result of the small sample size, we were unable to explore the associations in men and women separately, or adjust for potential confounders. We, therefore, decided to match the GSD1a patients with controls based on factors that are known to have a substantial effect on serum SHBG levels. Despite adequate matching, however, it cannot be excluded that there may be residual confounding. Another limitation of this study is that we were unable to account for phase of menstrual cycle or endogenous sex hormone levels. Nevertheless, the phase of menstrual cycle is likely to have scattering effects, as de novo lipogenesis varies throughout the menstrual cycle, while serum SHBG levels remain constant [35, 36]. Despite this scattering effect, we did observe a statistically significant difference in serum SHBG levels between GSD1a patients and controls. A possible effect of endogenous oestrogens or androgens on de novo lipogenesis and serum SHBG deserves further investigation. Furthermore, as a result of the extensive matching, data for healthy controls had to be retrieved from several studies. The in- and exclusion criteria varied between the studies, and, consequently, controls originating from the FRUITLESS study are metabolically less healthy when compared to the general population [16]. This could explain the relatively low serum SHBG levels in the control group, and, hence, could have mitigated the difference in serum SHBG levels between GSD1a and controls. Finally, because of the extreme phenotype of GSD1a, there may have been pleiotropic effects that have contributed to the current findings. For instance, given the fasting intolerance in GSD1a, all measures in patients with GSD1a were conducted after (modified) uncooked cornstarch at night or continuous nocturnal feeding with dextrose (but before breakfast). This may have affected some of the fasting-sensitive outcome measures including serum triglycerides, insulin and glucose. Of note, previous studies have shown that a recent meal only mildly affects IHL content [37]. The IHL content in GSD1a patients in the current study was much higher than what can be expected from a recent meal. Furthermore, previous studies have shown that serum SHBG levels are not affected by a recent meal [38].

In conclusion, in the present study we found that patients with GSD1a, who are characterized by genetically-determined higher rates of de novo lipogenesis, have statistically significantly lower levels of serum SHBG than controls.

Declarations

Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Research involving human participants and/or animals All studies were performed according to the Declaration of Helsinki and approved by the Medical Ethical Committee of Maastricht University Medical Centre.

Consent to participate Written informed consent was obtained from all participants.

References

1. Hammond GL, Wu TS, Simard M (2012) Evolving utility of sex hormone-binding globulin measurements in clinical medicine. Curr Opin Endocrinol Diabetes Obes 19(3):183–189
2. Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295(11):1288–1299
3. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM (2015) The association of obesity with sex hormone-binding globulin is stronger than the association with ageing–implications for the interpretation of total testosterone measurements. Clin Endocrinol 83(6):828–833
4. Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S (2017) Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 16(3):382–394
5. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, Beaumont RN, Wittemans L, Martin S, Busch AS et al (2020) Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med 26(2):252–258
6. Stefan N, Häring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9(3):144–152
7. Selva DM, Hogeveen KN, Innis SM, Hammond GL (2007) Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Investig 117(12):3979–3987
8. Simons PIHG, Valkenburg O, Telgenkamp I, van der Waaij KM, de Groot DM, Veeraiah P, Bons JAP, Taskinen M-R, Borén J, Schrauwen P et al (2021) Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans. Clin Endocrinol 95(1):101–106
9. Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Dyer RA, Innis SM, Simó R, Selva DM (2017) Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development. Endocrinology 158(3):545–559
10. Sáez-López C, Salcedo-Allende MT, Hernandez C, Simó-Servat O, Simó R, Selva DM (2019) Sex hormone-binding globulin expression correlates with acetyl-coenzyme a carboxylase and triglyceride content in human liver. J Clin Endocrinol Metab 104(5):1500–1507
11. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) Glycogen storage disease type I: Diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161(Suppl 1):S20–S34
12. Bandsma RH, Prinsen BH, van Der Velden MS, Rake JP, Boer T, Smit GP, Reijngoud DJ, Kuipers F (2008) Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 63(6):702–707
13. Roumans KHM, Lindeboom L, Veeraiah P, Remie CME, Phielix E, Havekes B, Bruls YMH, Brouwers MCGJ, Stålman M, Alssema M et al (2020) Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat Commun 11(1):1891
14. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM (2015) The association of obesity with sex hormone-binding globulin is stronger than the association with ageing—implications for the interpretation of total testosterone measurements. Clin Endocrinol 83(6):828–833
15. Maggio M, Lauretani F, Basaria S, Ceda GP, Bandinelli S, Metter EJ, Bos AJ, Ruggiero C, Ceresini G, Paolisso G et al (2008) Sex hormone binding globulin levels across the adult lifespan in women—the role of body mass index and fasting insulin. J Endocrinol Invest 31(7):597–601
16. Simons N, Veeraiah P, Simons PIHG, Schaper NC, Kooi ME, Schrauwen-Hinderling VB, Feskens EJM, van der Ploeg EMC, Van den Eynde MDG, Schalkwijk CG et al (2020) Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am J Clin Nutr 113(2):391–400
17. Simons N, Debray F-G, Schaper NC, Kooi ME, Feskens EJM, Hollak CEM, Lindeboom L, Koek GH, Bons JAP, Lefeber DJ et al (2019) Patients with aldolase b deficiency are characterized by increased intrahepatic triglyceride content. J Clin Endocrinol Metab 104(11):5056–5064
18. Association WM (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194
19. Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, Chung WK, Dagli AI, Dale D, Koeberl D et al (2014) Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genetics Med 16(11):e1–e29

20. Mairovitz V, Labrune P, Fernandez H, Audibert F, Frydman R (2002) Contraception and pregnancy in women affected by glycogen storage diseases. Eur J Pediatr 161(1):S97–S101

21. Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, Blankenstein MA, Fauser BCJM (2014) The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 20(1):76–105

22. Aarsand A, Fernandez-Calle P, Webster C, Coskun A, Gonzales-Lao E, Diaz-Garzon J, Jonker N, Minchinela J, Simon M, Braga F et al. The EFLM Biological Variation Database. https://biologicalvariation.eu/

23. Belgorosky A, Rivarola MA (1982) Sex hormone-binding globulin response to human chorionic gonadotropin stimulation in children with cryptorchidism, anorchia, male pseudohermaphroditism, and micropenis. J Clin Endocrinol Metab 54(4):698–704

24. Hoogerland JA, Peeks F, Hijmans BS, Wolters JC, Kooijman S, Bos T, Bleeker A, van Dijk TH, Wolters H, Gerding A et al (2021) Impaired very-low-density lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia. J Inherit Metab Dis 44(4):879–892

25. Santoro N, Caprio S, Pierpont B, Van Name M, Savoye M, Parks EJ (2015) Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab 100(8):E1125–E1132

26. Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S, Collins FS, Gloyn AL (2012) Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55(1):114–122

27. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PRV, Orho-Melander M, Gloyn AL (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18(21):4081–4088

28. Lin YC, Chang PF, Chang MH, Ni YH (2014) Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 99(4):869–874

29. Brouwers MCGJ, Jacobs C, Bast A, Stehouwer CDA, Schaper NC (2015) Modulation of glucokinase regulatory protein: a double-edged sword? Trends Mol Med 21(10):583–594

30. Coviello AD, Haring R, Wellons M, Vaidya D, Lehtimäki T, Keildson S, Lunetta KL, He C, Fornage M, Lagou V et al (2012) A genome-wide association meta-analysis of circulating sex hormone–binding globulin reveals multiple loci implicated in sex steroid hormone regulation. PLoS Genet 8(7):e1002805

31. Lee PJ, Patel A, Hindmarsh PC, Mowat AP, Leonard JV (1995) The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: Its association with hyperinsulinism. Clin Endocrinol 42(6):601–606

32. Sechi A, Deroma L, Lapolla A, Paci S, Melis D, Burlina A, Carubbi F, Rigoldi M, Di Rocco M (2013) Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. J Inherit Metab Dis 36(1):83–89

33. Selby C (1990) Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem 27(Pt 6):532–541

34. Froissart R, Piraud M, Boudjemline AM, Vianey-Saban C, Petit F, Hubert-Buron A, Eberschweiler PT, Gajdos V, Labrune P (2011) Glucose-6-phosphatase deficiency. Orphanet J Rare Dis 6(1):27

35. Jia MC, Zhou LY, Ren S, Dong L, Xiao B (1992) Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept 8(1):33–40

36. Faix D, Neese R, Kletke C, Wolden S, Cesar D, Coutlangus M, Shackleton CH, Hellerstein MK (1993) Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans. J Lipid Res 34(12):2063–2075

37. Lindeboom L, Nabuurs CI, Hesselink MK, Wildberger JE, Schrauwen P, Schrauwen-Hinderling VB (2015) Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. Am J Clin Nutr 101(1):65–71

38. Habito RC, Ball MJ (2001) Postprandial changes in sex hormones after meals of different composition. Metabolism 50(5):505–511